COGNITION THERAPEUTICS INC (CGTX)
Cognition Therapeutics Announces New Composition of Matter Patent, Extending Patent Protection for Lead Candidate, Zervimesine (CT1812) Through 2045
Cognition Therapeutics Announces New Composition of Matter Patent, Extending Patent Protection for Lead Candidate, Zervimesine (CT1812) Through 2045
📈 **POSITIVE** • High confidence analysis (89%) • Strong positive clinical catalyst • Significant growth potential **Sentiment:** Positive (95%) **Content type:** Clinical